Skip navigation

Tracking Emerging State Pricing Transparency, Reporting & Disclosure Laws to Ensure Compliance

December 5, 2017
  • Philadelphia, PA

Drug pricing regulation remains in the headlines — state legislatures across the country continue to introduce and pass laws aimed at limiting drug pricing and adding obligations around transparency and reporting. The recent passage of California’s drug pricing bill and a number of other states passing laws earlier in 2017 leaves many unanswered questions and the opportunity to steer the course is now.

CBI’s one-day Drug Pricing Transparency Congress convenes stakeholders across the healthcare ecosystem, including state and federal government regulators, manufacturers, health plans, PBMs, associations and other industry experts to learn how the future of drug pricing transparency regulation impacts commercialization, reimbursement and drug pricing models with a focus on state pricing and transparency regulation.

Join us to learn what’s driving the increasing emergence of state laws and proposed objectives of the legislation. Attendees will leave this event with critical state-by-state analysis of recently enacted transparency and reporting obligations and tactical next steps to ensure compliance.

Featured Discussion Topics:

  • The Latest Developments in State Transparency and
    Disclosure Legislation and the Impact on Commercialization
  • State Pricing Transparency Legal and Enforcement Overview — What You Need to Know to Ensure Reporting Compliance — Key State-by-State Analysis
  • Compliance and Operational Impact Analysis for State Transparency Tracking and Reporting Obligations
  • Understanding Value Based Frameworks and
    the Overall Impact on Drug Pricing
  • Drug Pricing Scrutiny — The “New” Normal

... and many more drug pricing and transparency focused topics.

Drug Pricing Transparency Congress

Tracking Emerging State Pricing Transparency, Reporting & Disclosure Laws to Ensure Compliance

Drug pricing regulation remains in the headlines — state legislatures across the country continue to introduce and pass laws aimed at limiting drug pricing and adding obligations around transparency and reporting. The recent passage of California’s drug pricing bill and a number of other states passing laws earlier in 2017 leaves many unanswered questions and the opportunity to steer the course is now.

CBI’s one-day Drug Pricing Transparency Congress convenes stakeholders across the healthcare ecosystem, including state and federal government regulators, manufacturers, health plans, PBMs, associations and other industry experts to learn how the future of drug pricing transparency regulation impacts commercialization, reimbursement and drug pricing models with a focus on state pricing and transparency regulation.

Join us to learn what’s driving the increasing emergence of state laws and proposed objectives of the legislation. Attendees will leave this event with critical state-by-state analysis of recently enacted transparency and reporting obligations and tactical next steps to ensure compliance.

Featured Discussion Topics:

  • The Latest Developments in State Transparency and
    Disclosure Legislation and the Impact on Commercialization
  • State Pricing Transparency Legal and Enforcement Overview — What You Need to Know to Ensure Reporting Compliance — Key State-by-State Analysis
  • Compliance and Operational Impact Analysis for State Transparency Tracking and Reporting Obligations
  • Understanding Value Based Frameworks and
    the Overall Impact on Drug Pricing
  • Drug Pricing Scrutiny — The “New” Normal

... and many more drug pricing and transparency focused topics.